These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37343080)

  • 1. An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor.
    Reyes Gaido OE; Pavlaki N; Granger JM; Mesubi OO; Liu B; Lin BL; Long A; Walker D; Mayourian J; Schole KL; Terrillion CE; Nkashama LJ; Hulsurkar MM; Dorn LE; Ferrero KM; Huganir RL; Müller FU; Wehrens XHT; Liu JO; Luczak ED; Bezzerides VJ; Anderson ME
    Sci Transl Med; 2023 Jun; 15(701):eabq7839. PubMed ID: 37343080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca
    Bezzerides VJ; Caballero A; Wang S; Ai Y; Hylind RJ; Lu F; Heims-Waldron DA; Chambers KD; Zhang D; Abrams DJ; Pu WT
    Circulation; 2019 Jul; 140(5):405-419. PubMed ID: 31155924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium/calmodulin-dependent protein kinase II contributes to cardiac arrhythmogenesis in heart failure.
    Sag CM; Wadsack DP; Khabbazzadeh S; Abesser M; Grefe C; Neumann K; Opiela MK; Backs J; Olson EN; Brown JH; Neef S; Maier SK; Maier LS
    Circ Heart Fail; 2009 Nov; 2(6):664-75. PubMed ID: 19919992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibition ameliorates arrhythmias elicited by junctin ablation under stress conditions.
    Tzimas C; Terrovitis J; Lehnart SE; Kranias EG; Sanoudou D
    Heart Rhythm; 2015 Jul; 12(7):1599-610. PubMed ID: 25814413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Ruan Y; Denegri M; Bachetti T; Li Y; Colombi B; Napolitano C; Coetzee WA; Priori SG
    J Mol Cell Cardiol; 2011 Jan; 50(1):214-22. PubMed ID: 20937285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CaMKII inhibition has dual effects on spontaneous Ca
    Sadredini M; Haugsten Hansen M; Frisk M; Louch WE; Lehnart SE; Sjaastad I; Stokke MK
    Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H446-H460. PubMed ID: 34270372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CaMKII inhibition rescues proarrhythmic phenotypes in the model of human ankyrin-B syndrome.
    DeGrande S; Nixon D; Koval O; Curran JW; Wright P; Wang Q; Kashef F; Chiang D; Li N; Wehrens XH; Anderson ME; Hund TJ; Mohler PJ
    Heart Rhythm; 2012 Dec; 9(12):2034-41. PubMed ID: 23059182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel CaMKII inhibitor GS-680 reduces diastolic SR Ca leak and prevents CaMKII-dependent pro-arrhythmic activity.
    Lebek S; Plößl A; Baier M; Mustroph J; Tarnowski D; Lücht CM; Schopka S; Flörchinger B; Schmid C; Zausig Y; Pagratis N; Marchand B; Koltun DO; Hung WK; Ahmadyar S; Belardinelli L; Maier LS; Wagner S
    J Mol Cell Cardiol; 2018 May; 118():159-168. PubMed ID: 29614261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of SR Ca
    Neef S; Mann C; Zwenger A; Dybkova N; Maier LS
    Basic Res Cardiol; 2017 Jul; 112(4):45. PubMed ID: 28612156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel CaMKII-δ Inhibitor Hesperadin Exerts Dual Functions to Ameliorate Cardiac Ischemia/Reperfusion Injury and Inhibit Tumor Growth.
    Zhang J; Liang R; Wang K; Zhang W; Zhang M; Jin L; Xie P; Zheng W; Shang H; Hu Q; Li J; Chen G; Wu F; Lan F; Wang L; Wang SQ; Li Y; Zhang Y; Liu J; Lv F; Hu X; Xiao RP; Lei X; Zhang Y
    Circulation; 2022 Apr; 145(15):1154-1168. PubMed ID: 35317609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospholamban ablation rescues the enhanced propensity to arrhythmias of mice with CaMKII-constitutive phosphorylation of RyR2 at site S2814.
    Mazzocchi G; Sommese L; Palomeque J; Felice JI; Di Carlo MN; Fainstein D; Gonzalez P; Contreras P; Skapura D; McCauley MD; Lascano EC; Negroni JA; Kranias EG; Wehrens XH; Valverde CA; Mattiazzi A
    J Physiol; 2016 Jun; 594(11):3005-30. PubMed ID: 26695843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidized CaMKII (Ca
    Wang Q; Quick AP; Cao S; Reynolds J; Chiang DY; Beavers D; Li N; Wang G; Rodney GG; Anderson ME; Wehrens XHT
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005682. PubMed ID: 29654126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium-calmodulin kinase II mediates digitalis-induced arrhythmias.
    Gonano LA; Sepúlveda M; Rico Y; Kaetzel M; Valverde CA; Dedman J; Mattiazzi A; Vila Petroff M
    Circ Arrhythm Electrophysiol; 2011 Dec; 4(6):947-57. PubMed ID: 22009705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
    Mustroph J; Wagemann O; Lücht CM; Trum M; Hammer KP; Sag CM; Lebek S; Tarnowski D; Reinders J; Perbellini F; Terracciano C; Schmid C; Schopka S; Hilker M; Zausig Y; Pabel S; Sossalla ST; Schweda F; Maier LS; Wagner S
    ESC Heart Fail; 2018 Aug; 5(4):642-648. PubMed ID: 30117720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ca
    Baier MJ; Klatt S; Hammer KP; Maier LS; Rokita AG
    J Mol Cell Cardiol; 2020 Jan; 138():212-221. PubMed ID: 31836540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium-calmodulin-dependent protein kinase mediates the intracellular signalling pathways of cardiac apoptosis in mice with impaired glucose tolerance.
    Federico M; Portiansky EL; Sommese L; Alvarado FJ; Blanco PG; Zanuzzi CN; Dedman J; Kaetzel M; Wehrens XHT; Mattiazzi A; Palomeque J
    J Physiol; 2017 Jun; 595(12):4089-4108. PubMed ID: 28105734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.
    Di Pasquale E; Lodola F; Miragoli M; Denegri M; Avelino-Cruz JE; Buonocore M; Nakahama H; Portararo P; Bloise R; Napolitano C; Condorelli G; Priori SG
    Cell Death Dis; 2013 Oct; 4(10):e843. PubMed ID: 24113177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor.
    Neef S; Steffens A; Pellicena P; Mustroph J; Lebek S; Ort KR; Schulman H; Maier LS
    J Mol Cell Cardiol; 2018 Feb; 115():73-81. PubMed ID: 29294328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise training prevents ventricular tachycardia in CPVT1 due to reduced CaMKII-dependent arrhythmogenic Ca2+ release.
    Manotheepan R; Danielsen TK; Sadredini M; Anderson ME; Carlson CR; Lehnart SE; Sjaastad I; Stokke MK
    Cardiovasc Res; 2016 Aug; 111(3):295-306. PubMed ID: 27161030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CaMKII
    Kreitmeier KG; Tarnowski D; Nanadikar MS; Baier MJ; Wagner S; Katschinski DM; Maier LS; Sag CM
    Am J Physiol Heart Circ Physiol; 2021 Mar; 320(3):H1199-H1212. PubMed ID: 33449853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.